FT522

N/A

Report date: 2023/07/21 20:00:29

Base Information

Drug NameFT522

Drug Alias NameFT522FT-522

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsImmune System DiseasesLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A